why choose us

First received: July 24, 2025

Clinical Trial: Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: COVID-19

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Dose Escalation Study to Assess the Safety, Reactogenicity, and Immunogenicity of STX-S for Prevention of SARS-CoV-2 Infection as a Booster Dose

Brief Summary: This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of STX-S in adults who have previously received a primary series and at least one booster with an authorized or licensed SARS-CoV-2 parenteral vaccine. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating three dose levels of STX-S. A sample size of 60 participants (20 participants per dose cohort) is anticipated. The primary objective is to evaluate the safety and reactogenicity of…

Read more